As shown in Figure 7, since the filing of the main compound patents in 2006, Novo Nordisk has been applying for patents consistently over a period of 17 years, with heavier patenting activity in 2019, two years before Wegovy was approved
The medication is supplied in single-dose prefilled pens containing 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg doses
For weight management, these effects translate into reduced hunger and, when the user does eat, a longer-lasting feeling of satiation
To lose weight effectively, you'll want to create a calorie deficit, which means eating fewer calories than you burn